← Evidence library

BIB_166

Patel SP et al. Neoadjuvant-adjuvant or adjuvant-only pembrolizumab in advanced melanoma (SWOG S1801). NEJM 2023;388(9):813–823. PMID 36856617. n=313 resectable Stage IIIB-IV; EFS HR 0.58 favouring neoadjuvant. [Tasks: 17, 18] Tier: 1 Grade: A Retrieved: 2026-05-07

Evidence grade

A

Tier

1

Cited by tasks

17, 18

Identifiers

PMID:36856617

↗ Follow the original source for full context

Full extracted findings & patient-implication analysis: bibliography/BIB_166/findings.md (research corpus). This page is a short context summary — not individualised medical advice.